STUDY OBJECTIVE: To investigate the prevalence and potential risk factors of thrombocytopenia in hospitalized patients receiving valproic acid (VPA) for psychiatric indications (excluding epilepsy). DESIGN: Retrospective study SETTING: University-affiliated psychiatric facility. PATIENTS: Two hundred sixty-four patients treated with VPA. INTERVENTION: Data from patients hospitalized between January 1, 1994, and December 31, 1998, who were receiving VPA and had at least one platelet count recorded. MEASUREMENTS AND MAIN RESULTS: Of 264 VPA-treated patients, 31 (12%) met our criteria for thrombocytopenia. Mild thrombocytopenia (platelet count of 101-150 x 10(3)/mm3) occurred in 25 (9%) patients, and moderate thrombocytopenia (platelet count of 40-100 x 103/mm3) occurred in 6 (2%) patients. Age older than 65 years (p=0.02) and VPA dosage greater than 1,000 mg/day (p<0.001) were identified as significant risk factors for developing thrombocytopenia. CONCLUSION: The estimated prevalence of thrombocytopenia is 12% in the general psychiatric population receiving VPA, with the elderly at greatest risk.
STUDY OBJECTIVE: To investigate the prevalence and potential risk factors of thrombocytopenia in hospitalized patients receiving valproic acid (VPA) for psychiatric indications (excluding epilepsy). DESIGN: Retrospective study SETTING: University-affiliated psychiatric facility. PATIENTS: Two hundred sixty-four patients treated with VPA. INTERVENTION: Data from patients hospitalized between January 1, 1994, and December 31, 1998, who were receiving VPA and had at least one platelet count recorded. MEASUREMENTS AND MAIN RESULTS: Of 264 VPA-treated patients, 31 (12%) met our criteria for thrombocytopenia. Mild thrombocytopenia (platelet count of 101-150 x 10(3)/mm3) occurred in 25 (9%) patients, and moderate thrombocytopenia (platelet count of 40-100 x 103/mm3) occurred in 6 (2%) patients. Age older than 65 years (p=0.02) and VPA dosage greater than 1,000 mg/day (p<0.001) were identified as significant risk factors for developing thrombocytopenia. CONCLUSION: The estimated prevalence of thrombocytopenia is 12% in the general psychiatric population receiving VPA, with the elderly at greatest risk.
Authors: Donna C Davidson; Michael P Hirschman; Sherry L Spinelli; Craig N Morrell; Giovanni Schifitto; Richard P Phipps; Sanjay B Maggirwar Journal: J Immunol Date: 2010-11-29 Impact factor: 5.422
Authors: Demi S Post; Arian van der Veer; Olaf E M G Schijns; Sylvia Klinkenberg; Kim Rijkers; G Louis Wagner; Vivianne H J M van Kranen-Mastenbroek; Paul C P H Willems; Paul W M Verhezen; Erik A M Beckers; Floor C J I Heubel-Moenen; Yvonne M C Henskens Journal: PLoS One Date: 2022-02-25 Impact factor: 3.240